NordicTrip
Nordic Breast Group

FLOW SHEET, Year one
Regime A

Name, personal identifier			Starting dose	Dose-Level -1	Dose-Level -2	Dose Level -3
		Epirubicin (mg/m^2)	90	75	60	Discontinue
		Cyclophosphamide (mg/m^2)	600	500	400	Discontinue

Height (cm):	Weight (kg):	Surface (m^2):	Reduce starting dose-level in the presence of severe co-morbidity

Year		Week no.	0	1		2	3		4	5		6	7	
		Day, month												
			1. cycle			2. cycle			3. cycle			4. cycle		
Epirubicin (mg)														
Cyclophosphamide (mg)														
Growth factor support	0=no, 1=yes													
Pembrolizumab (mg)														
Ovarian function suppression	0=no, 1=yes													
Zoledronic acid (mg)														

Hematological toxicity If absolute neutrophil count (ANC) < 1.0 x 10^9/L on a day of planned treatment postpone treatment until ANC ≥1.0 and if ANC 0.5-0.9 on day one keep starting dose. On the second occasion reduce by one level. If ANC<0.5 postpone until ANC≥1.0 and reduce by one dose level. If platelets < 100 x 10^9/L on a day of planned treatment postpone treatment until platelets ≥100 and keep dose level if platelets 50-99 (reduce by one dose level on second occasion) and if platelets <50 reduce by one dose level.

Enter														
on day 1	Neutrophils (x10^9/L)													
	Leucocytes (x10^9/L)													
	Haemoglobine (mmol/L)													
	Thrombocytes (x10^9/L)													

Non-hematological toxicity Grade 3 and 4 should result in dose reduction

Febrile neutropenia	0 – 4													
Mouth or throat sores	0 – 2													
Nausea	0 – 2													
Vomiting	0 – 4													
Diarrhea	0 – 4													
Rash	0 – 2													
Hand-foot syndrome	0 – 2													
Myalgia	0 – 2													
Arthralgia	0 – 2													
Numbness & tingling	0 – 4													
Cooling gloves used	0=no, 1=yes													
Fatigue	0 – 2													
Missed expected menses	0=no, 1=yes													
Other, add text	0 – 4													
Other, add text	0 – 4													

In case of any grade 3 or 4 toxicity make a record in the study specific CRF or eJournal of day of start and resolution as well as relation to the study drugs (related, possible related, or not related).

NordicTrip
Nordic Breast Group

FLOW SHEET, Year one
Regime A

Name, personal identifier		Starting dose	Dose-Level -1	Dose-Level -2	Dose Level -3
	Paclitaxel (mg/m^2), A +C	80	65	50	Discontinue
	Carboplatin (AUC), C	5	4	3	Discontinue

Height (cm):	Weight (kg):	Surface (m^2):	Reduce starting dose-level in the presence of severe co-morbidity

Year	Week no.	9	10	11	12	13	14	15	16	17	18	19	20
	Day, month												
		5. cycle			6. cycle			7. cycle			8. cycle		
Paclitaxel (mg), iv. day 1+8+15													
Carboplatin (mg), iv. day 1													
Growth factor support	0=no, 1=yes												
Pembrolizumab (mg)													
Ovarian function suppression	0=no, 1=yes												
Zoledronic acid (mg)													

Hematological toxicity If absolute neutrophil count (ANC) < 1.0 x 10^9/L on a day of planned treatment postpone treatment until ANC ≥1.0 and **add** growth factor support. On the second occasion reduce by one level. If platelets < 100 x 10^9/L on a day of planned treatment postpone treatment until platelets ≥100 and reduce by one dose level.

Enter on day 1													
	Neutrophils (x10^9/L)												
	Leucocytes (x10^9/L)												
	Hemoglobin (mmol/L)												
	Thrombocytes (x10^9/L)												

Renal function

On day 1	GFR ml/min												

Non-hematological toxicity Grade 3 and 4 should result in dose reduction

Febrile neutropenia	0 – 4												
Mouth or throat sores	0 – 2												
Nausea	0 – 2												
Vomiting	0 – 4												
Diarrhea	0 – 4												
Rash	0 – 2												
Hand-foot syndrome	0 – 2												
Myalgia	0 – 2												
Arthralgia	0 – 2												
Numbness & tingling	0 – 4												
Cooling gloves used	0=no, 1=yes												
Fatigue	0 – 2												
Missed expected menses	0=no, 1=yes												
Other, add text	0 – 4												
Other, add text	0 – 4												

In case of any grade 3 or 4 toxicity make a record in the study specific CRF or eJournal of day of start and resolution as well as relation to the study drugs (related, possible related, or not related).